EBITDA of the I-direct healthcare universe is expected to grow 10% YoY to | 9616 crore. EBITDA margins are likely to grow just 47 bps YoY to 24.3%. Sharp price erosion in the US base business may be offset by US exclusivities and growth in emerging markets. Net profit is expected to increase ~9% YoY to | 5779 crore, in line with the operational performance. On the regulatory front, Divi's Lab's Vizag API plant (unit-II) received USFDA import alert. However, USFDA has exempted 12 APIs from the import alert. Indoco Remedies has received warning letters from the USFDA for its Goa...